BioLineRx to Present at the 2013 BIO CEO & Investor Conference in New York on February 12th
Dr. Savitsky and Mr. Serlin are scheduled to present at
A live Webcast of the presentation will be available on the BioLineRx Website at http://www.biolinerx.com/default.asp?pageid=63&itemid=155. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.
Investors or potential partners attending the conference that wish to meet with Dr. Savitsky or Mr. Serlin for a one-on-one meeting should contact the BIO Partnering Team at biopartnering@bio.org.
About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of six clinical stage candidates:
BL-1020 for schizophrenia is currently undergoing a Phase II/III study;
BL-1040, for prevention of pathological cardiac remodeling following a
myocardial infarction, which has been out-licensed to
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s
Source: BioLineRx
KCSA Strategic Communications
Garth Russell, 1-212-896-1250
grussell@kcsa.com
or
Todd
Fromer, 1-212-896-1250
tfromer@kcsa.com
or
Tsipi
Haitovsky, Public Relations
+972-3-6240871
tsipih@netvision.net.il